IMRX ▼ -2.4% - Immuneering Corporation
$IMRX - Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026
26-OCT-2026 07:30 AM ET
Share this post
More filings for $IMRX
IMRX ▲ +1.6% - Immuneering CorporationNov 12, 2026IMRX ▼ -1.9% - Immuneering CorporationNov 9, 2026IMRX ▼ -0.3% - Immuneering CorporationNov 4, 2026IMRX ▲ +0.5% - Immuneering CorporationOct 29, 2026IMRX ▲ +4.2% - Immuneering CorporationOct 2, 2026IMRX ▲ +2.1% - Immuneering CorporationSep 28, 2026
View full $IMRX filing history →💬 Comments
Loading comments…
Leave a comment